Description

Upadacitinib is a potent and selective Janus kinase 1 (JAK1) inhibitor, representing a significant advancement in targeted immunomodulatory therapy. Its high selectivity profile offers a refined mechanism of action for managing inflammatory and autoimmune conditions. This active pharmaceutical ingredient (API) is essential for pharmaceutical manufacturers and research institutions developing treatments for rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, and ulcerative colitis.

Application

• Pharmaceutical API: Primary active ingredient in the formulation of oral tablets for the treatment of moderate to severe rheumatoid arthritis (RA).
• Immunology Research: Critical tool for biochemical and pharmacological research into JAK-STAT signaling pathways and their role in autoimmune diseases.
• Dermatology Therapeutics: Used in the development of systemic treatments for severe atopic dermatitis (eczema) in adults and adolescents.
• Gastroenterology Drug Development: Key component in therapies for ulcerative colitis and other immune-mediated gastrointestinal disorders.
• Psoriatic Arthritis Treatment: Incorporated into medications designed to inhibit the progression of active psoriatic arthritis.
• Reference Standard: Serves as a high-purity analytical standard for quality control and regulatory testing in pharmaceutical laboratories.
• Preclinical & Clinical Studies: Utilized in the synthesis of formulations for non-clinical safety assessments and clinical trial materials.

Basic Information

Product Name	Upadacitinib
CAS No.	1310726-60-3
Molecular Formula	C17H19F3N6O
Molecular Weight	380.37 g/mol
Synonyms	ABT-494; Rinvoq™ (Brand Name); (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide; (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide; JAK1 Inhibitor ABT-494; Upadacitinib free base
EINECS	Contact for details

Quality Control

Our Upadacitinib is manufactured under strict quality management systems, targeting purity levels suitable for pharmaceutical development and commercial API use. Each batch is subjected to comprehensive analytical testing including HPLC for assay and impurity profiling, residual solvent analysis (GC), and chiral purity verification. A detailed Certificate of Analysis (COA) is provided with every shipment, ensuring traceability and compliance with ICH Q7 guidelines and current Good Manufacturing Practices (cGMP).

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic nature, the container must be kept tightly sealed in a dry environment to prevent moisture absorption. For long-term storage, consider using desiccants.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.5%
Related Substances (HPLC)	Total impurities ≤1.5% Any single unknown impurity ≤0.10%
Chiral Purity (HPLC)	≥99.5%
Residual Solvents (GC)	Complies with ICH Q3C
Water Content (KF)	≤0.5%
Residue on Ignition	≤0.1%
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.